Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2013

01.12.2013 | Translational Research and Biomarkers

Expression of Brachyury Gene Is a Significant Prognostic Factor for Primary Lung Carcinoma

verfasst von: Akira Haro, MD, Tokujiro Yano, MD, Mikihiro Kohno, MD, Tsukihisa Yoshida, MD, Takaomi Koga, MD, Tatsuro Okamoto, MD, Mitsuhiro Takenoyama, MD, Yoshihiko Maehara, MD

Erschienen in: Annals of Surgical Oncology | Sonderheft 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

The clinical significance of Brachyury expression and its relationship to epithelial–mesenchymal transition in primary lung carcinoma is unclear.

Methods

Expression of Brachyury mRNA was investigated in 104 surgically resected primary lung carcinoma tissues. Immunohistochemical analysis of Brachyury transcription factor, Slug, E-cadherin, IL-8, N-cadherin, and Ki67 was performed in 67 of 104 cases, and their expression was correlated to prognoses and clinicopathological factors.

Results

Brachyury mRNA expression in primary lung carcinoma tissues was a significant predictor of poor prognosis for 5-year disease-free survival and overall survival rates and was significantly correlated to vascular invasion, lymphatic permeation, histological grade, pathologic T stage, and pathologic N stage (P < 0.05). Brachyury mRNA expression was significantly inversely correlated to E-cadherin expression (P = 0.0252) and positively correlated to IL-8 protein (P = 0.0241) and to Slug protein (P = 0.0243) in adenocarcinoma tissues.

Conclusions

A positive association between Brachyury and Slug and IL-8, and a negative association with E-cadherin may lead to invasiveness and metastasis in primary lung carcinoma. Brachyury mRNA expression is a significant predictor of poor prognosis in primary lung carcinoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef
2.
Zurück zum Zitat Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non–small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006;59:790–800.PubMedCrossRef Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non–small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006;59:790–800.PubMedCrossRef
3.
Zurück zum Zitat Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997;277:225–8.PubMedCrossRef Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997;277:225–8.PubMedCrossRef
4.
Zurück zum Zitat Radisky ES, Radisky DC. Matrix metalloproteinase–induced epithelial–mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:201–12.PubMedCrossRef Radisky ES, Radisky DC. Matrix metalloproteinase–induced epithelial–mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:201–12.PubMedCrossRef
5.
Zurück zum Zitat Xu J, Rodriguez D, Petitclerc E, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 2001;154:1069–79.PubMedCrossRef Xu J, Rodriguez D, Petitclerc E, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 2001;154:1069–79.PubMedCrossRef
6.
Zurück zum Zitat Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.PubMedCrossRef Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.PubMedCrossRef
7.
Zurück zum Zitat Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial–mesenchymal transition of human carcinoma cells. Cancer Res. 2011;71:5296–306.PubMedCrossRef Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial–mesenchymal transition of human carcinoma cells. Cancer Res. 2011;71:5296–306.PubMedCrossRef
8.
Zurück zum Zitat Fernando RI, Litzinger M, Trono P, et al. The T-box transcription factor Brachyury promotes epithelial–mesenchymal transition in human tumor cells. J Clin Invest. 2010;120:533–44.PubMedCrossRef Fernando RI, Litzinger M, Trono P, et al. The T-box transcription factor Brachyury promotes epithelial–mesenchymal transition in human tumor cells. J Clin Invest. 2010;120:533–44.PubMedCrossRef
9.
Zurück zum Zitat Roselli M, Fernando RI, Guadagni F, et al. Brachyury, a driver of the epithelial–mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res. 2012;18:3868–79. Roselli M, Fernando RI, Guadagni F, et al. Brachyury, a driver of the epithelial–mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res. 2012;18:3868–79.
10.
Zurück zum Zitat Palena C, Polev DE, Tsang KY, et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res. 2007;13:2471–8.PubMedCrossRef Palena C, Polev DE, Tsang KY, et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res. 2007;13:2471–8.PubMedCrossRef
11.
Zurück zum Zitat Kilic N, Feldhaus S, Kilic E, et al. Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer. 2011;47:1080–5.PubMedCrossRef Kilic N, Feldhaus S, Kilic E, et al. Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer. 2011;47:1080–5.PubMedCrossRef
12.
Zurück zum Zitat Krukovskaia LL, Polev DE, Nosova Iu K, et al.[Investigation of transcription factor Brachyury (T) expression in human normal and tumor tissues] Vopr Onkol. 2008;54:739–43.PubMed Krukovskaia LL, Polev DE, Nosova Iu K, et al.[Investigation of transcription factor Brachyury (T) expression in human normal and tumor tissues] Vopr Onkol. 2008;54:739–43.PubMed
13.
Zurück zum Zitat Park JC, Chae YK, Son CH, et al. Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochem Biophys Res Commun. 2008;365:221–6.PubMedCrossRef Park JC, Chae YK, Son CH, et al. Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochem Biophys Res Commun. 2008;365:221–6.PubMedCrossRef
14.
Zurück zum Zitat Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28.PubMedCrossRef Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28.PubMedCrossRef
15.
Zurück zum Zitat Huber MA, Kraut N, Beug H. Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548–58.PubMedCrossRef Huber MA, Kraut N, Beug H. Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548–58.PubMedCrossRef
16.
Zurück zum Zitat Storci G, Sansone P, Trere D, et al. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol. 2008;214:25–37.PubMedCrossRef Storci G, Sansone P, Trere D, et al. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol. 2008;214:25–37.PubMedCrossRef
17.
Zurück zum Zitat Zhang K, Chen D, Jiao X, et al. Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling. Lab Invest. 2011;91:426–38.PubMedCrossRef Zhang K, Chen D, Jiao X, et al. Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling. Lab Invest. 2011;91:426–38.PubMedCrossRef
18.
Zurück zum Zitat Shih JY, Tsai MF, Chang TH, et al. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res. 2005;11:8070–8.PubMedCrossRef Shih JY, Tsai MF, Chang TH, et al. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res. 2005;11:8070–8.PubMedCrossRef
19.
Zurück zum Zitat Chou TY, Chen WC, Lee AC, et al. Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Cell Signal. 2009;21:704–11.PubMedCrossRef Chou TY, Chen WC, Lee AC, et al. Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Cell Signal. 2009;21:704–11.PubMedCrossRef
20.
Zurück zum Zitat Cai M, Onoda K, Takao M, et al. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non–small cell lung cancer. Clin Cancer Res. 2002;8:1152–6.PubMed Cai M, Onoda K, Takao M, et al. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non–small cell lung cancer. Clin Cancer Res. 2002;8:1152–6.PubMed
21.
Zurück zum Zitat Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11:573–87.PubMedCrossRef Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11:573–87.PubMedCrossRef
22.
Zurück zum Zitat Kubo F, Ueno S, Hiwatashi K, et al. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol. 2005;12:800–7.PubMedCrossRef Kubo F, Ueno S, Hiwatashi K, et al. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol. 2005;12:800–7.PubMedCrossRef
23.
Zurück zum Zitat Bates RC, DeLeo MJ, 3rd, Mercurio AM. The epithelial–mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res. 2004;299:315–24.PubMedCrossRef Bates RC, DeLeo MJ, 3rd, Mercurio AM. The epithelial–mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res. 2004;299:315–24.PubMedCrossRef
24.
Zurück zum Zitat Kase S, Sugio K, Yamazaki K, et al. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000;6:4789–96.PubMed Kase S, Sugio K, Yamazaki K, et al. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000;6:4789–96.PubMed
25.
Zurück zum Zitat Masuya D, Huang C, Liu D, et al. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer. 2001;92:2628–38.PubMedCrossRef Masuya D, Huang C, Liu D, et al. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer. 2001;92:2628–38.PubMedCrossRef
26.
Zurück zum Zitat Chen JJ, Yao PL, Yuan A, et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003;9:729–37.PubMed Chen JJ, Yao PL, Yuan A, et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003;9:729–37.PubMed
27.
Zurück zum Zitat Orditura M, De Vita F, Catalano G, et al. Elevated serum levels of interleukin-8 in advanced non–small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res. 2002;22:1129–35.PubMedCrossRef Orditura M, De Vita F, Catalano G, et al. Elevated serum levels of interleukin-8 in advanced non–small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res. 2002;22:1129–35.PubMedCrossRef
28.
Zurück zum Zitat Yuan A, Yang PC, Yu CJ, et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med. 2000;162:1957–63.PubMedCrossRef Yuan A, Yang PC, Yu CJ, et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med. 2000;162:1957–63.PubMedCrossRef
29.
Zurück zum Zitat Sobin L. TNM classification of malignant tumors. 6th rev ed. New York: Wiley-Liss, 2002. Sobin L. TNM classification of malignant tumors. 6th rev ed. New York: Wiley-Liss, 2002.
30.
Zurück zum Zitat Yuan A, Yu CJ, Luh KT, et al. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol. 2002;20:900–10.PubMedCrossRef Yuan A, Yu CJ, Luh KT, et al. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol. 2002;20:900–10.PubMedCrossRef
31.
Zurück zum Zitat Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–8.PubMedCrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–8.PubMedCrossRef
32.
Zurück zum Zitat Sanchez-Mora N, Presmanes MC, Monroy V, et al. Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. Hum Pathol. 2008;39:324–30.CrossRef Sanchez-Mora N, Presmanes MC, Monroy V, et al. Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. Hum Pathol. 2008;39:324–30.CrossRef
33.
Zurück zum Zitat Moon KC, Cho SY, Lee HS, et al. Distinct expression patterns of E-cadherin and beta-catenin in signet ring cell carcinoma components of primary pulmonary adenocarcinoma. Arch Pathol Lab Med. 2006;130:1320–5.PubMed Moon KC, Cho SY, Lee HS, et al. Distinct expression patterns of E-cadherin and beta-catenin in signet ring cell carcinoma components of primary pulmonary adenocarcinoma. Arch Pathol Lab Med. 2006;130:1320–5.PubMed
34.
Zurück zum Zitat Prudkin L, Liu DD, Ozburn NC, et al. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009;22:668–78.PubMedCrossRef Prudkin L, Liu DD, Ozburn NC, et al. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009;22:668–78.PubMedCrossRef
Metadaten
Titel
Expression of Brachyury Gene Is a Significant Prognostic Factor for Primary Lung Carcinoma
verfasst von
Akira Haro, MD
Tokujiro Yano, MD
Mikihiro Kohno, MD
Tsukihisa Yoshida, MD
Takaomi Koga, MD
Tatsuro Okamoto, MD
Mitsuhiro Takenoyama, MD
Yoshihiko Maehara, MD
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe Sonderheft 3/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-2914-9

Weitere Artikel der Sonderheft 3/2013

Annals of Surgical Oncology 3/2013 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.